ArticleOncotarget2017

Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients.

Tao Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.